



LEUVEN

March 8 – 9 2018



Table of Contents

WORD OF WELCOME.....	3
ORGANIZING COMMITTEE.....	4
FULL PROGRAM	5
OVERVIEW.....	5
DETAILED WG PROGRAM	6
PARTICIPANTS.....	10
POSTER SESSIONS	15
WELCOME TO LEUVEN.....	17
SIGHTSEEING IN LEUVEN	18
FOOD AND DRINKS IN LEUVEN.....	21
TRAVELLING WITHIN LEUVEN	23
HOW TO REACH THE THERMOTECHNISCH INSTITUUT	25
LEUVEN CITY MAP	29
WIRELESS INTERNET ACCESS.....	30

Word of Welcome

Dear participant,

Welcome to Leuven, Belgium for the first ever UNGAP meeting. UNGAP, The European Network on Understanding Gastrointestinal Absorption-related Processes (UNGAP), aims to advance the field of intestinal drug absorption. During this meeting, key stakeholders will focus on four major challenges: differences between specific patient populations (WG1), regional differences along the gastrointestinal tract (WG2), the intraluminal behaviour of advanced formulations (WG3), and the food-drug interface (WG4). Experts in these research domains will provide insight into these topics through lectures, and you can present and discuss your work with fellow PhD students and professors through the poster sessions. By doing so, we work together towards the integration of knowledge and stimulate the exchange of best practices across sectors and disciplines.

WG1 and WG2 will be covered on Thursday 8 March, and lectures will take place in the Thermotechnisch Instituut. Afterwards you are welcome to join your colleagues for a reception in the city hall of Leuven, followed by a nice dinner. On Friday 9 March WG3 and WG4 will be the topics of interest.

UNGAP would not have been possible without the support of the European Cooperation in Science and Technology (COST), for which we are very grateful.

We hope that this first ever UNGAP meeting in Leuven will be a rewarding experience for all of you and spurs future developments in the field of pharmaceutical sciences.

Welcome to UNGAP,

The organizing committee

Organizing Committee



Patrick Augustijns
*Chair Organizing
Committee*



Philippe Berben
*Registration
Accommodation*



Glenn Lemmens
*Booklet
Website*



Jari Rubbens
Catering



Arno Van Camp
Accommodation



Marlies Braeckmans
Registration



Jenny Vijverman
Refunds

Full Program

Overview

Thursday March 8	Friday March 9
<i>Thermotechnisch Instituut (Kasteelpark 41 3001 Heverlee)</i>	<i>Thermotechnisch Instituut (Kasteelpark 41 3001 Heverlee)</i>
8:30 Registration	9:00 Welcome
9:00 Welcome	9:15 – 12:00 WG3 – meeting
9:15 – 12:00 WG1 – meeting	12:00 – 12:15 Summary of actions for WG3
12:00 – 12:15 Summary of actions for WG1	12:15 - 13:45 Lunch and poster presentation
12:15 - 13:45 Lunch and poster presentation	13:45 – 16:50 WG4 – meeting
13:45 – 16:50 WG2 – meeting	16:50 – 17:00 Summary of actions for WG4
16:50 – 17:00 Summary of actions for WG2	17:00 Concluding remarks
19:00 Reception City Hall (Grote markt)	
20:00 Dinner	

Detailed WG Program

WG1 Meeting (08 March 2018, 08.30 – 12.15)

How the differences in GI absorption of special populations impact the stages of drug product development: Opinion of key stakeholders

08.30 Registration & Poster

09.00 Welcome

Prof. Patrick Augustijns, KU Leuven

09.15 Introduction

*Dr. Mine Orlu, UCL School of Pharmacy
Dr. Katarina Vucicevic, University of Belgrade*

09.30 Altered GI absorption in special populations: An academic opinion

Prof. Sandra Klein, University of Greifswald

10.00 Altered GI absorption in special populations: An industrial opinion

Dr. Cordula Stillhart, Hoffmann-La Roche

10.30 Coffee break

11.00 Altered GI absorption in special populations: A clinical opinion

Dr. Daniel Keszthelyi, Maastricht University

11.30 Altered GI absorption in special populations: A regulatory opinion

Dr. Diana van Riet-Nales, Medicines Evaluation Board

12.00 Summary of actions

Dr Katarina Vucicevic, University of Belgrade

WG2 meeting (08 March 2018, 13.45 – 17.00)

Regional differences along the GI tract

13.45 Introduction

Dr. Maria Vertzoni, National and Kapodistrian University of Athens

13.50 From motility to models

Prof. Clive Wilson, University of Strathclyde

14.20 Update on motility of the gastrointestinal tract in health and disease

Prof. Tim Vanuytsel, University of Leuven

14.50 The stomach and beyond: impact of gastric motility on (variability in) oral drug disposition

Dr. Jens Van Den Abeele, Janssen Pharmaceutica

15.20 Coffee break

15.50 In vitro tools to simulate the regional differences of the human GI tract

Dr. Mirko Koziolok, University of Greifswald

16.20 In silico tools to simulate the regional differences of the human GI tract

Dr. Konstantinos Stamatopoulos, Certara

16.50 Summary of actions for WG2

Dr. Maria Vertzoni, National and Kapodistrian University of Athens

WG3 meeting (09 March 2018, 09.00 – 12.15)

Intraluminal behaviour of advanced formulations

09.00 Introduction

Dr. Vincent Jannin, Gattefossé

Intraluminal behaviour of advanced formulations: small molecules

09.15 Lipid-based formulations - impact of lipolysis on colloid formation and drug solubilization

Dr. Vincent Jannin, Gattefossé

09.30 Behavior of polymeric particles in the lumen and interaction with the intestinal epithelium

Prof. Gilles Ponchel, Université Paris Sud

09.45 Discussion with WG members

Intraluminal behaviour of advanced formulations: nucleic acids

10.00 Oral pDNA delivery: Accomplishments so far and challenges ahead

Prof. Andreas Bernkop-Schnürch, University of Innsbruck

10.15 Coffee Break

10.45 Oral delivery of RNAi-based nano-therapeutics, formulation approach and therapeutic applications

Prof. Caitriona O'Driscoll, University College Cork

11.00 Discussion with WG members

11.15 Modelling and simulation approaches to support formulation selection - discussion included

Dr. Donato Teutonico, Servier

12.00 Summary of actions for WG3

Prof. Gilles Ponchel, Université Paris Sud

WG4 meeting (09 March 2018, 13.45-17.00)

The food-drug interface

13:45 Introduction

Dr. Mirko Koziolok, University of Greifswald

13:50 Food-drug interactions - regulatory aspects

Dr. Henrike Potthast, BfArM

14:20 In vivo tools to study food-drug interactions

Prof. Werner Weitschies, University of Greifswald

14:50 Digestive processes in the GI tract and their impact on the fate of oral drugs and formulations

Prof. Frederic Carriere, University of Marseille

15:20 Coffee Break

15:50 In vitro tools to study food-drug/food-formulation interactions

Dr. James Butler, GSK

16:20 In silico tools to study food-drug interactions

Dr. Neil Parrott, Roche

16:50 Conclusions

Prof. Maura Corsetti, University of Nottingham

Participants

SURNAME	FIRST NAME	EMAIL ADDRESS	AFFILIATION	COUNTRY	WG1	WG2	WG3	WG4	WG5
Alcaro	Stefano	alcaro@unicz.it	Università Magna Graecia di Catanzaro	Italy				WG4	
Alsenz	Jochem	Jochem.Alsenz@roche.com	F. Hoffmann-La Roche AG	Switzerland			WG3		
Augustijns	Patrick	patrick.augustijns@kuleuven.be	KU Leuven	Belgium	WG1	WG2	WG3	WG4	WG5
Baczek	Tomasz	tbaczek@amg.gda.pl	Medical University of Gdansk	Poland			WG3	WG4	WG5
Berben	Philippe	philippe.berben@kuleuven.be	KU Leuven	Belgium			WG3	WG4	
Bergström	Christel	christel.bergstrom@farmaci.uu.se	Uppsala University	Sweden	WG1		WG3		
Bernkop-Schnürch	Andreas	andreas.bernkop@uibk.ac.at	University of Innsbruck	Austria			WG3		
Bevernage	Jan	jbeverna@its.jnj.com	Janssen	Belgium		WG2		WG4	WG5
Bogataj	Marija	marija.bogataj@ffa.uni-lj.si	University of Ljubljana, Faculty of Pharmacy	Slovenia				WG4	
Bogatko	Stuart	SBogatko@its.jnj.com	Janssen R&D	Belgium		WG2		WG4	
Borde	Anders	Anders.Borde@Astrazeneca.com	AstraZeneca Gothenburg	Sweden		WG2			
Bouillon	Thomas	Thomas.bouillon@kuleuven.be	KU Leuven	Belgium	WG1				
Braeckmans	Marlies	marlies.braeckmans@kuleuven.be	Kuleuven	Belgium		WG2		WG4	
Brandl	Martin	mmb@sdu.dk	University of Southern Denmark	Denmark			WG3		
Brouwers	Joachim	joachim.brouwers@kuleuven.be	KU Leuven	Belgium			WG3	WG4	
Butler	James	james.m.butler@gsk.com	GlaxoSmithKline	UK	WG1			WG4	
Carriere	Frederic	carriere@imm.cnrs.fr	Centre National de la Recherche Scientifique	France			WG3	WG4	WG5
Castleberry	Steven	steven.castleberry@abbvie.com	AbbVie						
Ceulemans	Jens	jceulem3@its.jnj.com	Janssen Pharmaceutica	Belgium			WG3	WG4	
Corsetti	Maura	maura.corsetti@nottingham.ac.uk	nottingham university	UK	WG1			WG4	
Cvetkovski	Aleksandar	aleksandar.cvetkovski@ugd.edu.mk	University Goce Delcev, R. Macedonia	R. Macedonia			WG3	WG4	
Dadeshidze	Inga	inga.dadeshidze@cost.eu	Action Science Officer	Belgium					
de Wildt	Saskia	saskia.dewildt@radboudumc.nl	Radboudumc	Netherlands	WG1				
Devold	Tove	tovede@nmbu.no	Norwegian University of Life Sciences	Norway				WG4	

10

UNGAP, Leuven 2018

Dubbelboer	Ilse	ilse.dubbelboer@farmaci.uu.se	Uppsala University	Sweden		WG2			
Eisinaite	Viktorija	viktorija.eisinaite@ktu.lt	Kaunas University of Technology	Lithuania			WG3	WG4	
Elvang	Philipp Alexander	elvang@sdu.dk	University of Southern Denmark	Denmark		WG2		WG4	
Falavigna	Margherita	margherita.falavigna@uit.no	University of Tromsø, The Arctic University of Norway	Norway		WG2			
Garbacz	Grzegorz	g.garbacz@physiolution.pl	Physiolution	Poland			WG2	WG3	
García-Horsman	J. Aruro	Arturo.Garcia@helsinki.fi	University of Helsinki	Finland		WG2	WG3		
Geldof	Marian	marian.geldof@unilever.com	Unilever R&D Vlaardingen	Netherlands				WG4	WG5
Gjorgjeva Ackova	Darinka	darinka.gjorgjeva@ugd.edu.mk	University Goce Delcev - Stip, Macedonia FYR	Macedonia				WG4	
Griesser	Janine	j.griesser@thiomatrix.com	Thiomatrix	Austria			WG3		
Gutman	Roeie	roeeg@migal.org.il	MIGAL – Galilee Research Institute	Israel			WG3	WG4	
Hansmann	Simone	Simone.hansmann@external.merckgroup.com	Merck KGaA Darmstadt	Germany		WG2		WG4	
Holm	Rene	rholm@its.jnj.com	Janssen	Belgium	WG1	WG2	WG3	WG4	
Holmstock	Nico	nholmsto@ITS.JNJ.com	Janssen	Belgium			WG3	WG4	
Jacobsen	Ann-Christin	acj@sdu.dk	University of Southern Denmark	Denmark			WG3	WG4	
Jannin	Vincent	vjannin@gattefosse.com	Gattefosse SAS	France			WG3		WG5
Jede	Christian	Christian.Jede@external.merckgroup.com	Ernst Moritz Arndt Universität Greifswald	Germany		WG2	WG3		
Jensen	Klaus	KGJ@lundbeck.com	Lundbeck A/S	Denmark	WG1			WG4	
Jimenez	Marcel	marcel.jimenez@uab.cat	Universitat Autònoma de Barcelona	Spain		WG2		WG4	
Jug	Mario	mjug@pharma.hr	University of Zagreb	Croatia			WG3		
Kateb	Jens	JKAT@lundbeck.com	Lundbeck	Denmark	WG1	WG2	WG3	WG4	WG5
Katev	Vladimir	vk@lcpe.uni-sofia.bg	Sofia University St. Kliment Ohridski	Bulgaria				WG4	
Keszthelyi	Daniel	daniel.keszthelyi@maastrichtuniversity.nl	Maastricht University Medical Center	Netherlands	WG1				
Khadra	Ibrahim	ibrahim.khadra@strath.ac.uk	University of Strathclyde	UK			WG3	WG4	
Klein	Sandra	Sandra.Klein@uni-greifswald.de	University of Greifswald	Germany	WG1			WG4	
Koskinen	Mikko	mikko.koskinen@orionpharma.com	Orion Corporation Orion Pharma	Finland	WG1				
Koziolek	Mirko	mirko.koziolek@uni-greifswald.de	University of Greifswald	Germany		WG2		WG4	
Krisl	Albin	kristia@ffa.uni-lj.si	University of Ljubljana, Faculty of Pharmacy	Slovenia		WG2			
Kubačková	Jana	kubackovaj@gmail.com	Faculty of Pharmacy in Hradec Králové, Charles University	Czech Republic			WG3		

11

Larsen	Frank	FRL@lundbeck.com	Lundbeck A/S	Denmark	WG1	WG2	
Lemmens	Glenn	glenn.lemmens@kuleuven.be	KU Leuven	Belgium	WG1	WG2	
Leskauskaite	Daiva	daiva.leskauskaite@ktu.lt	Kaunas University of Technology	Lithuania			WG4
Lima	Sofia	slima@ff.up.pt	REQUIMTE, University of Porto	Portugal		WG3	WG4
Maran	Uko	uko.maran@ut.ee	University of Tartu	Estonia		WG2	
Maruca	Annalisa	maruca@unicz.it	University Magna Graecia of Catanzaro	Italy			WG4
Matias	Ana	amatias@ibet.pt	IBET	Portugal		WG2	WG3
Matilainen	Laura	laura.matilainen@orionpharma.com	Orion Pharma	Finland			WG4
Matthys	Christophe	christophe.matthys@uzleuven.be	KU Leuven	Belgium	WG1		WG4
Meléndez-Martínez	Antonio	ajmelendez@us.es	Universidad De Sevilla	Spain			WG3
Mellaerts	Randy	randy.mellaerts@gmail.com	RMED	Belgium	WG1		WG4
Michna	Thomas	thomasmichna@hotmail.de	Janssen Pharmaceutica	Belgium	WG1	WG2	WG4
Miljuš	Goran	goranm@inep.co.rs	Institute for the Application of Nuclear Energy-INEP	Serbia		WG2	WG4
Müllertz	Anette	anette.mullertz@sund.ku.dk	University of Copenhagen	Denmark	WG1	WG2	WG3
Nata Guerreiro	Joana	joana.guerreiro@ibet.pt	IBET – Instituto de Biologia Experimental e Tecnológica	Portugal			WG3
Nicolai	Johan	johan.nicolai@ucb.com	UCB Biopharma Sprl	Belgium	WG1	WG2	
Nimavardi	Ali	ali.nimavardi@certara.com	Simcyp (A certara company)	UK			WG3
O'Driscoll	Caitriona	caitriona.odriscoll@ucc.ie	University College Cork Ireland	Ireland		WG2	WG3
Oja	Mare	mare.oja@ut.ee	University of Tartu	Estonia		WG2	
Onrej	Holas	holao3aa@faf.cuni.cz	Faculty of Pharmacy in Hradec Kralove, Charles University	Czech Republic			WG3
Orlu	Mine	m.orlu@ucl.ac.uk	UCL School of Pharmacy	UK	WG1		WG3
Palm	Johan	Johan.Palm@astrazeneca.com	AstraZeneca	Sweden	WG1		WG4
Pappinen	Sari	sari.pappinen@orionpharma.com	Orion	Finland		WG2	
Parrott	Neil	neil_john.parrott@roche.com	F Hoffmann LaRoche	CH	WG1		WG4
Pavek	Petr	pavek@faf.cuni.cz	Charles University	Czech Republic			WG4
Penttafragka	Christina	cpenttafragka@pharm.uoa.gr	National Kapodistrian University of Athens	Greece		WG2	WG4
Plum	Jakob	Jakob.plum@sund.ku.dk	University of Copenhagen	Denmark		WG2	WG3
Ponchel	Gilles	gilles.ponchel@u-psud.fr	Université Paris-Sud Paris-Saclay	France		WG2	WG3

12

Potthast	Henrike	henrike.potthast@bfarm.de	Federal Institute for Drugs and Medical Devices (BfArM)	Germany			WG4
Praphanwittaya	Pitsiree	pip3@hi.is	University of Iceland	Iceland		WG2	WG3
Reppas	Christos	reppas@pharm.uoa.gr	National and Kapodistrian University of Athens	Greece	WG1		WG4
Roganovic	Masa	masa@pharmacy.bg.ac.rs	Faculty of Pharmacy, University of Belgrade	Serbia	WG1		
Rubbens	Jari	rubbensjari@gmail.com	KU Leuven	Belgium		WG2	WG4
Sanchez-Dengra	Barbara	barbasanchezdengra@gmail.com	Universidad Miguel Hernandez de Elche	Spain		WG2	
Semjonov	Kristian	kristian.semjonov@gmail.com	University of Tartu	Estonia	WG1		WG3
Sironi	Daniel	sironi@sdu.dk	University of Southern Denmark	Denmark			WG3
Smilkov	Katarina	katarina.smilkov@ugd.edu.mk	Goce Delcev University	Macedonia			WG4
Stamatopoulos	Konstantinos	Konstantinos.Stamatopoulos@certara.com	Certara-Simcyp	UK			WG3
Stappaerts	Jef	jstappa1@its.jnj.com	Janssen	Belgium	WG1		WG3
Statelova	Marina	mstatelova@pharm.uoa.gr	National and Kapodistrian University of Athens	Greece	WG1		WG4
Steenackers	Nele	nele.steenackers@kuleuven.be	KU Leuven	Belgium	WG1		
Stillhart	Cordula	cordula.stillhart@roche.com	F. Hoffmann-La Roche	Switzerland	WG1		WG3
Šunderić	Miloš	milos@inep.co.rs	Institute for the Application of Nuclear Energy-INEP	Serbia		WG2	WG4
Sznitowska	Malgorzata	msznito@gumed.edu.pl	Medical University of Gdansk	Poland	WG1		WG3
Taherali	Farhan	farhan.taherali.15@ucl.ac.uk	University College London	United Kingdom		WG2	
Teutonico	Donato	donato.teutonico@servier.com	Servier	France	WG1		WG3
Thijs	Tim	tim.thijs@kuleuven.be	KU Leuven	Belgium			WG5
Tistaert	Christophe	ctistaer@its.jnj.com	Janssen R&D	Belgium	WG1	WG2	
Toader	Elena	toader.elena@yahoo.com	University of Medicine and Pharmacy "Grigore T. Popa"	Romania	WG1		WG3
Tuleu	catherine	c.tuleu@ucl.ac.uk	UCL	UK	WG1		WG4
Ungell	AnnaLena	annalena.ungell@ucb.com	UCB Biopharma sprl	Belgium	WG1	WG2	
Valentová	Kateřina	kata.valentova@email.cz	Institute of Microbiology of the Czech Academy of Sciences	Czech Republic			WG4
Van Camp	Arno	arno.vancamp@kuleuven.be	KU Leuven	Belgium		WG2	WG4
Van Den Abeele	Jens	JVanD122@its.jnj.com	KU Leuven	Belgium	WG1		WG3
Van den Mooter	Guy	guy.vandenmooter@kuleuven.be	KU Leuven	Belgium			WG3
van Groen	Bianca	b.vangroen@erasmusmc.nl	Erasmus MC - Sophia Children's Hospital and Radboudumc	The Netherlands	WG1		

13

Van Riet	Diana	da.v.riet@cbg-meb.nl	MEB	The Netherlands	WG1	WG2	WG3	WG4	WG5
Vanuytsel	Tim	tim.vanuytsel@uzleuven.be	UZ Leuven / KULeuven	Belgium	WG1	WG2			
Vertzoni	Maria	vertzoni@pharm.uoa.gr	National and Kapodistrian University of Athens	Greece	WG1	WG2		WG4	
Viitala	Tapani	tapani.viitala@helsinki.fi	University of Helsinki	Finland		WG2	WG3		
Vinarov	Zahari	zv@dce.uni-sofia.bg	Sofia University	Bulgaria			WG3		
Vicenti	Zúñiga García	viorenzo.germanstias@gencat.cat	University Hospitals Germans Trias/IGTP Barcelona	Spain	WG1		WG3		
Vitali Čepo	Dubravka	dvitali@pharma.hr	University of Zagreb, Faculty of Pharmacy and Biochemistry	Croatia				WG4	
Vucicevic	Katarina	kacav@pharmacy.bg.ac.rs	University of Belgrade-Faculty of Pharmacy	Serbia	WG1				
Weitschies	Werner	werner.weitschies@uni-greifswald.de	University of Greifswald	Germany		WG2		WG4	WG5
Wilson	Clive	clivegwilson@mac.com	University of Strathclyde	Scotland		WG2			
Zdovc	Jurij	jurij.zdovc@ffa.uni-lj.si	University of Ljubljana, Faculty of Pharmacy	Slovenia	WG1				

Poster sessions

Below is a list of all posters ranked alphabetically by last name, this list can help you to find posters you are interested in.

LAST NAME	POSTER TITLE	Poster number
Alcaro	Computational tools for investigating drug-food interaction	1
Augustijns	Intestinal drug absorption: What is happening inside and beyond?	2
Baczek	Pharmaceutical and biomedical analysis of drugs and endogenous substances supported by analytical and medicinal chemistry tools	3
Berben	Exploring parameters influencing high inter- but low intra-laboratory variability in dissolution testing	4
Bergström	Experimental and theoretical models to predict drug release, dissolution and absorption from the colon	5
Bogataj	Implementation of selected GI conditions (transit times, pH) in biorelevant dissolution systems	6
Brandl	The Dissolution-/Permeation-Behavior of Tadalafil	7
Corsetti	MRI as non-invasive tool to study in vivo the influence of GI function on drugs dissolution	8
Cvetkovski	Preliminary study on screening the intermolecular interactions of organic cation drugs from BSC Class III (case study Metformin)	9
Eisinaite	Bioavailability of vitamin D from food grade emulsions	10
Elvang	Mapping the phase behavior of artificial intestinal fluids by flow field-flow fractionation & light scattering - incl. Celecoxib as model drug	11
Falavigna	Mucus-PVPA : a permeability-screening tool for drug discovery and formulation development in mucosal tissues	12
Garbacz	Predictive dissolution testing	13
Griesser	Mucus permeating properties of self-emulsifying peptide drug delivery systems	14
Gutman	Holding Mice at an Environmental Photocycle that Matches their Endogenous Circadian Rhythm Period Length Prevents Diet-Induced Obesity	15
Jacobsen	Permeation behavior and supramolecular structures of mono- / diacyl solid phospholipid dispersions of celecoxib in simulated intestinal fluid.	16
Katev	Micellar Solubilization of Poorly Water-soluble Drugs: Effect of Surfactant and Solubilize Molecular Structure	17
Khadra	In-vitro and In-silico profiling to assist Drug Development	18
Koziolek	Exploring food-drug interactions: solubility screening of ziprasidone-HCl in biorelevant media	19
Kubackova	Preparation of polymeric nanocarriers for the treatment of inflammatory bowel disease	20
Lemmens	Pharmacokinetic disposition of cox-inhibitors for the prevention/treatment of colorectal cancer	21
Lima	Cellular uptake and transcytosis of lipid-based nanoparticles across the intestinal barrier	22
Maran	Characteristic pH-profiles of passive membrane permeability of chemical classes	23
Maruca	Computational tools for investigating Drug-Food Interactions	24

15

Meléndez-Martínez	Bioaccessibility of phytoene and phytofluene from fruit and vegetable juices as compared to other carotenoids	25
Müllertz	In vitro studies of drug solubilization, using a gastro-intestinal digestion model simulating the human neonatal population	26
Nata Guerreiro	Improving bioactives intestinal absorption using lipidic nanodelivery systems in food applications: evaluation of toxicity and bioavailability	27
Oja	Measuring and modelling pH-profile of membrane permeability	28
Parrott	Food effect predictions	29
Pavek	Steviol, an aglycone of steviol glycoside sweeteners, interacts with the pregnane X (PXR) and aryl hydrocarbon (AHR) receptors in detoxification regulation	30
Plum	Visualizing the Journey of Fenofibrate through the Rat Gastro-Intestinal Tract by Mass Spectrometry Imaging	31
Reppas	Clinically important absorption impairment due to bacterial degradation in the lower intestine: Can it be detected in vitro?	32
Roganovic	Predictive modeling: PBPK/PD and popPK/PD approach	33
Rubbens	Gastrointestinal behavior of diclofenac in healthy volunteers after intake of the FDA standard meal.	34
Semjonov	Development of melt-electrospun solid dispersions for improving solubility of poorly water-soluble drugs	35
Sironi	PermealLoop™ – a novel setup for dissolution/permeation studies	36
Steenackers	Gastrointestinal physiological conditions after Bariatric Surgery	37
Sznitowska	Pharmacokinetic information in Summary of Product Characteristics - critical review	38
Taherali	Does food have an effect on the intestinal mucosal barrier of male and female rats?	39
Thijs	Overview of UNPGAP Science Communication Activities	40
Toader	The impact of drug absorption modifying diseases in a tertiary care center in northeastern Romania	41
Valentová	Preparation of sulfated metabolites of flavonoids and flavonolignans by arylsulfotransferase from <i>Desulfotobacterium hafniense</i>	42
van Groen	Feasibility of a pediatric microdose study of oral [14C]midazolam to study the ontogeny of CYP3A-mediated drug metabolism	43
Viitala	Advanced label-free cell based analysis platform for assessing drug absorption and action	44
Vinarov	Effect of surfactants on drug solubility in biorelevant media	45

16